ACADIA Pharmaceuticals Inc.
ACADNASDAQHealthcare● Active
$21.56
$-0.16(-0.74%)
Market Cap$3.7B
P/E Ratio—
52W High$28.35
52W Low$19.69
ACADIA Pharmaceuticals Inc. (ACAD) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ACAD · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.07B | $0.96B | $0.73B | $0.52B | $0.48B |
| Cost of Revenue | $0.09B | $0.08B | $0.05B | $0.01B | $0.02B |
| Gross Profit | $0.98B | $0.88B | $0.68B | $0.51B | $0.47B |
| Gross Margin %(computed) | 91.69% | 91.46% | 93.70% | 98.03% | 96.05% |
| Operating Expenses | |||||
| R&D Expenses | $0.33B | $0.30B | $0.35B | $0.36B | $0.24B |
| G&A Expenses | $0.00B | $0.00B | $0.39B | $0.00B | $0.40B |
| Total Operating Expenses | $0.88B | $0.65B | $0.75B | $0.73B | $0.64B |
| Operating Income | $0.10B | $0.23B | ($0.07B) | ($0.22B) | ($0.17B) |
| Operating Margin %(computed) | 9.78% | 24.10% | -10.10% | -43.23% | -35.20% |
| Interest Income | $0.03B | $0.03B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.14B | $0.26B | ($0.05B) | ($0.21B) | ($0.17B) |
| Income Tax Expense | ($0.25B) | $0.03B | $0.01B | $0.00B | $0.00B |
| Net Income | $0.39B | $0.23B | ($0.06B) | ($0.22B) | ($0.17B) |
| Net Margin %(computed) | 36.49% | 23.64% | -8.44% | -41.76% | -34.67% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.32 | $1.37 | $-0.37 | $-1.34 | $-1.05 |
| Wtd Avg Shares | 0.17B | 0.17B | 0.16B | 0.16B | 0.16B |
| EBITDA | $0.14B | $0.10B | ($0.07B) | ($0.22B) | ($0.17B) |
| EBITDA Margin %(computed) | 12.96% | 10.46% | -9.34% | -42.84% | -34.51% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more ACADIA Pharmaceuticals Inc. data
About ACADIA Pharmaceuticals Inc. (ACAD) Income Statement
ACADIA Pharmaceuticals Inc. (ACAD) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ACAD reported revenue of $1.07B, gross profit of $0.98B (gross margin 91.69%), and net income of $0.39B — a net profit margin of 36.49%.
Frequently asked questions
ACAD · 4 questionsACADIA Pharmaceuticals Inc. (ACAD) reported revenue of $1.07B for 2025, up 11.9% year-over-year.
ACAD revenueACAD salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08